In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Biosimilars Business Strategies Financing

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Looking Ahead, Companies Predict Decline In Revenues

  • Analysis

Executive Summary

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, firms have started taking precautionary measures to avoid supply-chain disruptions.

Table

View full table

Topics

Related Companies

Tags:
Biosimilars Business Strategies Financing
Latest Headlines

Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics

Fujifilm Demonstrates Health Specialism With European HealthTech Spinout

Financing Quarterly Statistics, Q1 2024

Helping Organizations Deliver On KPIs And Giving Staff A Voice

See All
UsernamePublicRestriction

Register

IV124556

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By